Cowen and Company’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Cowen and Company’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-202,371	Closed	-$8.2K	–	722
2023 Q1	$8.2K	Buy	202,371 +80,114	+66%	+$5.53K	﹤0.01%	406
2022 Q4	$6.8K	Hold	122,257	–	–	﹤0.01%	443
2022 Q3	$5K	Hold	122,257	–	–	﹤0.01%	520
2022 Q2	$8K	Sell	122,257 -64,970	-35%	-$10.4K	﹤0.01%	518
2022 Q1	$35K	Buy	187,227 +8,880	+5%	+$3.6K	﹤0.01%	371
2021 Q4	$103K	Buy	178,347 +140,869	+376%	+$104K	0.01%	366
2021 Q3	$27K	Hold	37,478	–	–	﹤0.01%	455
2021 Q2	$39K	Sell	37,478 -10,444	-22%	-$9.38K	﹤0.01%	428
2021 Q1	$60K	Buy	+47,922	New	+$77.7K	﹤0.01%	374

Cowen and Company's EUCRW Position: Q2 2023 in Review

Cowen and Company sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 202,371 shares — an estimated $8.2K sold.

Cowen and Company first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $103K in Q4 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Cowen and Company reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Cowen and Company sold 202,371 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $8.2K.
Cowen and Company first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
Cowen and Company's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $103K in Q4 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Cowen and Company's 13F filing for Q2 2023, filed 7 Aug 2023.